APG Asset Management N.V. Increases Stock Holdings in Boston Scientific Co. (NYSE:BSX)

APG Asset Management N.V. increased its stake in Boston Scientific Co. (NYSE:BSX - Free Report) by 404.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,021,217 shares of the medical equipment provider's stock after buying an additional 818,675 shares during the period. APG Asset Management N.V. owned 0.07% of Boston Scientific worth $88,088,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BSX. TFC Financial Management Inc. boosted its holdings in shares of Boston Scientific by 308.8% in the fourth quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 210 shares during the period. Dunhill Financial LLC increased its stake in shares of Boston Scientific by 86.4% during the third quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider's stock valued at $28,000 after buying an additional 152 shares during the period. Global Wealth Strategies & Associates raised its holdings in shares of Boston Scientific by 423.7% in the fourth quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider's stock valued at $28,000 after acquiring an additional 250 shares in the last quarter. West Oak Capital LLC purchased a new stake in Boston Scientific in the fourth quarter worth about $29,000. Finally, Valley National Advisers Inc. grew its holdings in Boston Scientific by 262.4% during the 4th quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider's stock worth $35,000 after acquiring an additional 286 shares in the last quarter. Institutional investors own 89.07% of the company's stock.

Boston Scientific Stock Performance

Shares of NYSE:BSX traded up $1.02 during trading on Friday, hitting $93.66. The stock had a trading volume of 8,303,541 shares, compared to its average volume of 6,351,456. The stock has a 50-day simple moving average of $100.54 and a two-hundred day simple moving average of $94.02. The stock has a market capitalization of $138.53 billion, a price-to-earnings ratio of 74.93, a price-to-earnings-growth ratio of 2.79 and a beta of 0.73. Boston Scientific Co. has a 12-month low of $66.80 and a 12-month high of $107.17. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. On average, equities research analysts expect that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Daniel J. Brennan sold 15,087 shares of the firm's stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $105.07, for a total transaction of $1,585,191.09. Following the sale, the chief financial officer now owns 241,451 shares in the company, valued at approximately $25,369,256.57. This trade represents a 5.88 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the company's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $101.80, for a total transaction of $1,762,463.40. Following the completion of the transaction, the executive vice president now owns 5,502 shares of the company's stock, valued at approximately $560,103.60. This trade represents a 75.88 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 133,183 shares of company stock valued at $13,948,476. Company insiders own 0.50% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on BSX. Royal Bank of Canada upped their price target on shares of Boston Scientific from $105.00 to $116.00 and gave the stock an "outperform" rating in a research report on Thursday, February 6th. Deutsche Bank Aktiengesellschaft upgraded Boston Scientific from a "hold" rating to a "buy" rating and set a $108.00 target price for the company in a report on Friday, January 10th. Truist Financial cut their price target on Boston Scientific from $120.00 to $113.00 and set a "buy" rating on the stock in a report on Friday. Stifel Nicolaus upped their price objective on Boston Scientific from $100.00 to $115.00 and gave the stock a "buy" rating in a research note on Thursday, February 6th. Finally, Citigroup lifted their target price on Boston Scientific from $107.00 to $122.00 and gave the company a "buy" rating in a research note on Thursday, February 6th. Two analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $109.04.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.